The BRAF Pseudogene Functions as a Competitive Endogenous RNA and Induces Lymphoma In Vivo

Highlights
- The BRAF pseudogene functions as a ceRNA for BRAF in humans and mice
- Braf-rs1 overexpression promotes B cell lymphoma in mice
- Silencing of BRAFP1 affects MAPK signaling and proliferation of human cancer cells
- Genomic gains and aberrant expression of BRAFP1 are found in various human cancers

Authors
Florian A. Karreth, Markus Reschke, ..., Roberto Chiarle, Pier Paolo Pandolfi

Correspondence
ppandolf@bidmc.harvard.edu

In Brief
The in vivo evidence for the regulatory activity of pseudogenes has been lacking, and their role in disease progression has been correlative. This study now shows that transgenic expression of the BRAF pseudogene induces a malignancy in mice resembling human diffuse large B cell lymphoma, establishing its oncogenic function.
The BRAF Pseudogene Functions as a Competitive Endogenous RNA and Induces Lymphoma In Vivo

Florian A. Karreth,1 Markus Reschke,1 Anna Ruocco,1 Christopher Ng,1 Bjorn Chapuy,2 Valentine Léopold,1 Marcela Sjoberg,3 Thomas M. Keane,3 Akanksha Verma,4 Ugo Ala,1 Yvonne Tay,1,9 David Wu,5 Nina Seitzer,1 Martin Del Castillo Velasco-Herrera,1 Anne Bothmer,1 Jacqueline Fung,1 Fernanda Langellotto,6 Scott J. Rodig,7 Olivier Elemento,4 Margaret A. Shipp,3 Roberto Chiarle,6,8 and Pier Paolo Pandolfi 1,*

1Cancer Research Institute, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
3Experimental Cancer Genetics, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1HH, UK
4Department of Physiology and Biophysics, Institute for Computational Biomedicine, Weill Cornell Medical College, New York, NY 10021, USA
5Meyer Cancer Center, Weill Cornell Medical College, New York, NY 10021, USA
6Department of Pathology, Children’s Hospital and Harvard Medical School, Boston, MA 02215, USA
7Department of Pathology, Brigham and Women’s Hospital, Boston, MA 02115, USA
8Department of Molecular Biotechnology and Health Sciences, University of Torino, 10124 Torino, Italy
9Present address: Cancer Science Institute of Singapore and Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597
*Correspondence: ppandolf@bidmc.harvard.edu
http://dx.doi.org/10.1016/j.cell.2015.02.043

SUMMARY

Research over the past decade has suggested important roles for pseudogenes in physiology and disease. In vitro experiments demonstrated that pseudogenes contribute to cell transformation through several mechanisms. However, in vivo evidence for a causal role of pseudogenes in cancer development is lacking. Here, we report that mice engineered to overexpress either the full-length murine B-Raf pseudogene Braf-rs1 or its pseudo “CDS” or “3’ UTR” develop an aggressive malignancy resembling human diffuse large B cell lymphoma. We show that Braf-rs1 and its human ortholog, BRAFP1, elicit their oncogenic activity, at least in part, as competitive endogenous RNAs (ceRNAs) that elevate BRAF expression and MAPK activation in vitro and in vivo. Notably, we find that transcriptional or genomic aberrations of BRAFP1 occur frequently in multiple human cancers, including B cell lymphomas. Our engineered mouse models demonstrate the oncogenic potential of pseudogenes and indicate that ceRNA-mediated microRNA sequestration may contribute to the development of cancer.

INTRODUCTION

Over the past few years, remarkable progress has been made in establishing long non-coding RNAs (lncRNAs) as important regulators of various biological processes. Given their critical roles, it is not surprising that aberrant expression and/or function of lncRNAs are implicated in the development of diseases such as cancer (Gutschner and Diederichs, 2012).

Pseudogenes, a sub-class of IncRNA genes that developed from protein-coding genes but have lost the ability to produce proteins, have long been viewed as non-functional genomic relics of evolution (Poliseno, 2012). However, the vast majority of pseudogenes have protein-coding parental counterparts with which they share high sequence homology, which enables pseudogenes to participate in posttranscriptional regulation of their parental genes. Mechanisms of parental gene regulation include the formation of endogenous siRNAs (Tam et al., 2008; Watanabe et al., 2008), recruitment of regulatory proteins by pseudogene antisense RNAs to complementary sites in the parental gene to modulate chromatin remodeling and transcription (Hawkins and Morris, 2010; Johnsson et al., 2013), and competition for RNA-binding proteins or the translation machinery (Bier et al., 2009; Chiefari et al., 2010; Han et al., 2011).

We recently proposed that the high sequence homology enables pseudogenes to compete with their parental genes for a shared pool of common microRNAs (miRNAs) (Poliseno et al., 2010), thus regulating the latter’s expression as competitive endogenous RNA (ceRNAs) (Salmena et al., 2011). This mechanism is of particular relevance to cancer where pseudogenes are aberrantly expressed (Kalyana-Sundaram et al., 2012). Specifically, we demonstrated that pseudogenes of the frequently mutated cancer genes PTEN and KRAS function as ceRNAs in vitro (Poliseno et al., 2010). Moreover, we and others reported that miRNAs and non-coding RNAs may serve as ceRNAs that regulate each other through miRNA-dependent crosstalk (Cazalla et al., 2010; Cesana et al., 2011; Franco-Zorrilla et al., 2010).
2007; Hansen et al., 2013; Karreth et al., 2011; Libri et al., 2012; Marcinowski et al., 2012; Memczak et al., 2013; Sumazin et al., 2011; Tay et al., 2011; Wang et al., 2013), suggesting that pseudogenes regulate the expression of their parental genes in the context of larger networks of protein-coding and non-coding ceRNAs.

While sufficient data exist to demonstrate pseudogene functions in vitro, in vivo evidence for the regulatory activity of pseudogenes—either as ceRNAs or by any of the other above-mentioned mechanisms—is lacking, and their role in disease progression is correlative. Here, we describe a causal role for the Braf-rs1 pseudogene in the development of cancer.

RESULTS

The Braf-rs1 Pseudogene Regulates BRAF as a Dicer1-Dependent Manner

The BRAF pseudogene (BRAFP1) is overexpressed in various tumor types (Zou et al., 2009; Kalyana-Sundaram et al., 2012), suggesting that it may contribute to cancer development. We have shown that pseudogenes are able to regulate expression of their parental genes through sequestration of shared miRNAs (Poliseno et al., 2010), and BRAFP1-mediated elevation of BRAF may promote MAPK signaling and tumorigenesis. MiRNA predictions revealed that murine Braf-rs1 (Gm18189) and B-Raf are targeted by 54 and 114 miRNA families, respectively, 53 of which have in common. Similarly, human BRAFP1 and Braf-rs1 are targeted by 60 and 48 miRNA families, respectively, and share 40 (Figures S1A–S1D, Table S1). Thus, the BRAF pseudogene may operate as a ceRNA for BRAF in mice and humans. Indeed, ectopic expression of Braf-rs1 in NIH 3T3 fibroblasts and BRAFP1 in human PC9 and HeLa cancer cells elevated BRAF protein and ERK phosphorylation (Figures 1A and S1E). Importantly, B-Raf was critical for this effect, as the Braf-rs1-induced increase in pERK was negated by genetic deletion of B-Raf in B-Rafffibroblasts (Figure 1B). Moreover, expression of the BRAF pseudogene increased proliferation of NIH 3T3, PC9, and HeLa cells (Figures 1C, 1D, and S1F). Moderate B-Raf overexpression was sufficient to increase pERK expression, proliferation, and anchorage-independent growth of NIH 3T3 fibroblasts (Figures S1G–S1I), indicating that Braf-rs1-mediated elevation of B-Raf may be sufficient for the observed phenotype.

To test whether the effect of the BRAF pseudogene on BRAF expression and proliferation rates was dependent on miRNAs, we utilized cell lines lacking functional Dicer1, a ribonuclease critical for miRNA biogenesis and whose deficiency results in drastically reduced levels of mature miRNAs (Cummins et al., 2006; Ravi et al., 2012). Ectopic expression of Braf-rs1 increased expression of B-Raf and pERK and elevated proliferation of Dicer1-proficient murine sarcoma cells, but not that of isogenic Dicer1 knockout cells (Figures 1E and 1F). Similarly, overexpression of BRAFP1 in Dicer1-proficient human HCT116 colon cancer cells increased expression of BRAF and pERK and elevated proliferation, and these effects were abrogated in isogenic Dicer1 mutant HCT116 cells (Figures 1G and 1H). Thus, the BRAF pseudogene-induced effects are dependent on BRAF and Dicer1.

The BRAF Pseudogene Regulates BRAF as a Competitive Endogenous RNA

The finding that the BRAF pseudogene mediates its effect through mature miRNAs suggests that it may function as a ceRNA. To test this directly, we co-expressed BRAFP1 with a human BRAF-3′ UTR-luciferase reporter in Dicer1-proficient and -deficient HCT116 cells. BRAFP1 elevated the activity of the BRAF 3′ UTR-luciferase reporter in a Dicer1-dependent manner (Figure 2A), further supporting the notion that the crosstalk is mediated by mature miRNAs. To validate this result, we tested several predicted shared miRNAs in 3′ UTR-luciferase reporter assays. Three out of ten murine miRNAs (miR-134, miR-543, and miR-653) significantly repressed Braf-rs1 and B-Raf luciferase reporters (Figure 2B), suggesting that the crosstalk may be mediated at least in part by these three miRNAs.

Next, we determined the ability of Braf-rs1 to decay the dual targeting miRNAs miR-134, miR-543, and miR-653 from luciferase reporters carrying miRNA response elements (MREs). Braf-rs1 regulated the expression of the luciferase reporters, especially at lower miRNA concentrations (Figure 2C). Braf-rs1-mediated sequestration of the least potent of the three dual targeting miRNAs, miR-543, had the most robust effect on luciferase reporter activity (Figure 2C). These data suggest that both potency and abundance of the miRNAs may be important determinants for ceRNA crosstalk. In addition, Braf-rs1 was able to sequester endogenous miR-653, miR-134, and miR-543 from the respective luciferase-MRE reporters, and mutation of the MREs in Braf-rs1 abrogated this effect (Figure 2D). Similarly, four out of nine human miRNAs (miR-30a, miR-182, miR-876, and miR-590) were able to repress BRAF- and BRAFP1-luciferase reporters (Figure S2A). miR-30a, miR-182, and miR-876 were also efficiently sequestered from the respective MRE-luciferase reporters by BRAFP1, and mutation of these miRNA-binding sites reduced BRAFP1’s activity as a miRNA sponge (Figure S2B).

Generation of TRE-BPS Mice

As Braf-rs1 regulates the expression of B-Raf and MAPK signaling, we sought to investigate whether aberrant Braf-rs1 expression is oncogenic in vivo. To this end, we generated a transgenic allele containing murine Braf-rs1 under the control of a doxycycline (Dox)-inducible Tet-response element (TRE) and targeted it to the collagen A1 locus using Flp recombinase-mediated genomic integration (Beard et al., 2006) (Figures S2C and S2D). We isolated mouse embryonic fibroblasts (MEFs) from TRE-Braf-rs1 (henceforth referred to as TRE-BPS) mice to confirm that expression of the Braf-rs1 allele regulates B-Raf. Infection of MEFs with a tTA-expressing retrovirus resulted in 6- to 18-fold induction of Braf-rs1 expression (Figures 2E and S2E), as well as increased levels of B-Raf and pERK (Figure 2F) and proliferation (Figure 2G), confirming that the transgenic allele elicits effects similar to ectopic expression of Braf-rs1.

We used TRE-BPS MEFs to analyze the stoichiometry of B-Raf and Braf-rs1. First, we determined the absolute number of transcripts by qPCR using plasmids carrying Braf-rs1 and B-Raf as standards (Figure S2E). In TRE-BPS MEFs infected with a control retrovirus, B-Raf molecules were 13- to 26-fold more abundant than Braf-rs1, while in tTA-infected cells, the B-Raf:Braf-rs1 ratio
Figure 1. The BRAF Pseudogene Regulates BRAF in a Dicer1-Dependent Manner

(A) Western blot demonstrating increased BRAF and pERK expression upon ectopic BRAF pseudogene expression in mouse (NIH 3T3, left) and human (PC9, right) cells.

(B) Western blot of B-Raf(fl/fl) fibroblasts overexpressing Braf-rs1 or control (yellow fluorescent protein [YFP]) in the presence or absence of Adeno-Cre infection.

(C) Increased proliferation of NIH 3T3 fibroblasts upon ectopic Braf-rs1 expression.

(D) Increased proliferation of PC9 cells upon ectopic BRAFP1 expression.

(E and F) Western blot (E) and proliferation assay (F) of Dicer1FL/FL and Dicer1D/D murine sarcoma cells overexpressing Braf-rs1.

(G and H) Western blot (G) and proliferation assay (H) of Dicer1WT and Dicer1Mut human HCT116 colon cancer cells overexpressing BRAFP1.

Error bars represent mean ± SD. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001. See also Figure S1.
was between 1.3 and 2.5 (Figure S2E). RNA-sequencing (RNA-seq) analysis confirmed Braf-rs1 induction and found B-Raf: Braf-rs1 ratios in a range similar to that determined by qPCR (Figure S2F and data not shown). Next, we determined the number of molecules of miR-653, miR-134, and miR-543 in TRE-BPS MEFs by qPCR using standard curves. miRNA expression was not...
significantly affected upon transgene induction (Figure S2G, Table S2). Mir-653 was expressed at extremely low levels, likely precluding it from Braf-rs1/B-Raf ceRNA crosstalk in MEFs. Additional predicted miRNAs that are expressed in MEFs (Table S2) but were not further validated may also contribute to crosstalk. Hence, the stoichiometry of B-Raf, transgenic Braf-rs1, and some dual-targeting miRNAs fits well within the optimal crosstalk criteria that we have recently established (Ara et al., 2013), supporting the hypothesis that overexpression of Braf-rs1 increases B-Raf through its ceRNA activity.

**Braf-rs1 Causes Diffuse Large B Cell Lymphoma**

To induce global overexpression of Braf-rs1 in vivo, TRE-BPS mice were crossed to CAG-rtTA3 mice (Premvirut et al., 2011), and compound mutant animals and single mutant controls were placed on a Dox-containing diet at 3 weeks of age (Figure S3A). qPCR analysis after 4 weeks of Dox administration confirmed Braf-rs1 overexpression in all organs tested (Figure S3B). Following 4 months of Dox treatment, TRE-BPS; CAG-rtTA3 mice became moribund and had to be sacrificed after a median survival of 421 days (Figure 3A), while none of the single-mutant animals or compound mutants maintained on a regular diet developed similar symptoms. All moribund TRE-BPS; CAG-rtTA3 mice presented with splenomegaly (Figures 3B and 3C) and enlarged lymph nodes (Figure 3K).

Histological analysis revealed large tumor nodules involving the splenic white pulp (Figures 3D and 3E). Tumors consisted of large lymphoid cells admixed with numerous plasmablasts and plasma cells (Figure 3F). The mitotic rate was very high (Figure 3F), and the proliferation rate was markedly increased compared to normal white pulp (Figures 3G and 3C).

We determined the immunophenotype of the splenic tumors by flow cytometry when TRE-BPS; CAG-rtTA3 mice succumbed to the malignancy. The cell population expressing surface B220 was decreased in spleens (Figure 3H), while Gr-1+Mac-1+ cells were slightly increased and CD3+ cells were unchanged (Figures 3I and 3J). Lymph nodes displayed more B220+ cells, while CD3+ cells were less abundant (Figures 3L and 3M). Similar results were obtained when calculated as fold change relative to controls (Figures S3D–S3I). By immunohistochemistry, tumor cells stained positively for CD45R/B220 and IgG (Figures 4A and 4C) and negatively for CD3 (Figure 4B). Moreover, tumors were negative for the germinal center marker Bcl6 (Figure 4D) and strongly positive for Pten (Figure 4E), while residual germinal centers adjacent to the tumors were Bcl6 positive and Pten negative (Figures 4D and 4E). The decrease of B220 expression on the surface of tumor cells reflected the marked plasmacellular differentiation, as shown by the abundance of IgG+ cells. Overall, this phenotype was consistent with post-germinal center diffuse large B cell lymphoma.

We next determined the abundance of Braf-rs1, B-Raf, and miRNA molecules in spleens after short-term Dox exposure (10 days) and in lymphomas and control spleens after long-term Dox exposure. While endogenous Braf-rs1 expression was between 6- and 115-fold lower than B-Raf, expression of transgenic Braf-rs1 was comparable to B-Raf (Figures S3I–S3L). Expression of miR-134, miR-543, and miR-653 was not affected by Braf-rs1 overexpression (Figures S3M and S3N). Similar to MEFs, miR-653 was expressed at low levels, while miR-134 and miR-543 were expressed at levels that are amenable to ceRNA crosstalk (Figures S3M and S3N).

**Aggressive Lymphomas Are Transplantable and Depend on Braf-rs1 Expression**

Macroscopic lymphoma nodules were commonly observed in the kidneys, livers, and lungs of TRE-BPS; CAG-rtTA3 mice (Figure 4F and data not shown), and histological analysis revealed microscopic organ infiltration by lymphoma cells in all animals (Figures 4G–4I). Such tumor cells displayed a CD45R/B220+ and Mum1+ phenotype identical to the cells infiltrating spleens and lymph nodes (Figures 4J–4O). Additionally, heterozygous loss of Pten reduced the median survival of TRE-BPS; CAG-rtTA3 mice to 172 days (data not shown).

To further assess the tumorigenicity of Braf-rs1-induced lymphomas, we analyzed their transplantation potential. NSG mice injected with TRE-BPS; CAG-rtTA3 spleen cells had to be sacrificed 100–150 days after transplantation due to deteriorating health. Moreover, NSG mice transplanted with TRE-BPS; CAG-rtTA3; Pten−/− lymphoma cells had to be sacrificed after 80 days (data not shown). NSG recipients exhibited infiltrating lymphoma cells in spleens, livers, lungs, and kidneys (Figure 5A). These results suggest that Braf-rs1-induced lymphomas are transplantable and highly aggressive.

We next determined whether continuous expression of Braf-rs1 was required for tumor maintenance. TRE-BPS; CAG-rtTA3 receiving a Dox-diet were monitored by palpation and were taken off Dox chow once splenomegaly became apparent. Spleen sizes of these animals were subsequently measured using high-resolution ultrasound. Notably, enlarged spleens of all TRE-BPS; CAG-rtTA3 mice reduced in size, while spleens of control mice were unaffected (Figure 5B). Moreover, 40 days after weaning the mice off Dox chow, the histology (Figures 5C and 5D) and Mum1 expression pattern (Figures 5E and 5F) of the white pulp of TRE-BPS; CAG-rtTA3 spleens were comparable to controls, confirming that lymphomas had largely regressed.

**Braf-rs1 Regulates B-Raf In Vivo**

To determine whether Braf-rs1 functions as a ceRNA for B-Raf in vivo, we examined Braf-rs1-induced lymphomas for expression of B-Raf and pERK. Notably, Braf-rs1-induced lymphomas displayed increased levels of B-Raf and pERK (Figures 5G, 5H, and 5I) compared to adjacent normal white pulp. The difference in B-Raf and pERK levels between tumors and normal white pulp in the same mouse is likely due to positive selection of B cells that express the highest levels of Braf-rs1, B-Raf, and pERK.

We next analyzed whether MAPK signaling is critical for the growth of Braf-rs1-induced lymphomas. To this end, we treated NSG mice that were transplanted with Braf-rs1-induced lymphoma cells with the MEK inhibitor GSK1120212. Notably, treatment with GSK1120212 markedly impaired the ability of transplanted lymphomas to colonize the livers of NSG mice (Figure 5J). Moreover, Dox withdrawal reduced B-Raf and pERK expression in tumors, indicating that increased MAPK activation is stimulated by continuous Braf-rs1 expression (Figure S4B). These data suggest that Braf-rs1 elicits its oncogenic effects, at least in part, through B-Raf and the MAPK pathway.
Figure 3. Braf-rs1 Expression In Vivo Results in a Lymphoid Malignancy

BPS, TRE-BPS: CAG-rTA3 mice on Dox; control, TRE-BPS, or CAG-rTA3 mice on Dox here and in all figures.

(A) Survival of BPS and control mice.

(B and C) Size (B) and weight (C) of BPS and control mouse spleens.

(D and E) Photomicrograph of a spleen from a control (D) and BPS mouse (E).

(F) Higher-magnification photomicrograph showing tumor cells in a BPS spleen. White arrowheads denote plasma cells, and black arrowhead highlights a mitotic figure.

(G) Quantification of Ki-67 staining.

(H–J) Flow cytometry-based quantification of splenic B220+ (H), CD3+ (I), and Gr-1+/Mac-1+ (J) populations.

(K) Size of control and BPS mouse lymph nodes.

(L and M) Flow cytometry-based quantification of B220+ (L) and CD3+ (M) populations in lymph nodes.

Error bars represent mean ± SD. See also Figure S3.
Figure 4. *Braf* rs1 Induces Diffuse Large B Cell Lymphoma

(A) CD45R/B220 staining. Higher magnification inset shows staining of large lymphoma cells.
(B) CD3 staining. Higher-magnification inset shows positive staining of reactive T cells.
(C) IgG staining. Arrowheads denote plasma cells.
(D) Bcl6 staining. Lymphoma cells are negative, and residual germinal center is positive.
(E) Mum1 staining. Tumor cells are positive, and residual germinal center is negative.
(F) Photograph of control and BPS kidneys. Arrowheads denote tumor nodules.
(G–I) H&E staining of kidney (G), liver (H), and lung (I) sections from BPS mice.
(J–L) CD45R/B220 immunohistochemistry of kidney (J), liver (K), and lung (L) sections from BPS mice.
(M–O) Mum1 immunohistochemistry of kidney (M), liver (N), and lung (O) sections from BPS mice.
The “CDS” and “3’ UTR” of Braf-rs1 Possess Oncogenic Potential

Based on Braf-rs1’s ability to decoy miRNAs, we reasoned that shorter fragments of Braf-rs1 may be able to crosstalk with B-Raf through a subset of the shared miRNA pool. Such fragments would elicit similar phenotypes provided that the crosstalk remains robust. Alternatively, different portions of Braf-rs1 may regulate distinct ceRNA networks and yield distinct,

Figure 5. Lymphomas Are Transplantable, Are Addicted to Braf-rs1 Expression, and Activate the MAPK Pathway

(A) Transplanted lymphoma cells infiltrating the spleen, liver, kidney, and lungs of NSG recipient mice.
(B) Spleen size measurements after Dox withdrawal.
(C–F) H&E staining (C and D) and Mum1 immunohistochemistry (E and F) of BPS and control mouse spleens depicted in (B) after Dox withdrawal.
(G) Immunohistochemical staining for B-Raf of lymphoma and adjacent normal white pulp in BPS spleen.
(H) Immunohistochemical staining for pERK of lymphoma and adjacent normal white pulp in BPS spleen.
(I) Percentage of liver infiltration by TRE-BPS; CAG-rtTA3; Pten+/− lymphoma cells transplanted into NSG mice in response to GSK1120212 treatment. Each symbol represents a liver section, and each recipient mouse is color coded. Error bars represent mean ± SD. ***p ≤ 0.001. See also Figure S4.
B-Raf-unrelated phenotypes. To experimentally examine these possibilities, we generated two additional Dox-inducible mouse models overexpressing either the “CDS” or the “3’ UTR” of Braf-rs1 (Figures S2C and S2D). TRE-BPS CDS and TRE-BPS 3’UTR mice were crossed to CAG-rtTA3 mice and their offspring fed a Dox-containing diet for 6 months. Remarkably, both TRE-BPS CDS and TRE-BPS 3’UTR mice displayed enlarged spleens and lymph nodes similar to full-length TRE-BPS mice (Figures 6A and 6B).

Braf-rs1 3’UTR overexpression resulted in splenomegaly and reduced survival (Figures 6C and 6D and S5C) similar to TRE-BPS mice. The histology and immunophenotype of lymphomas in TRE-BPS 3’UTR mice were similar to that of full-length TRE-BPS animals (Figures 6E–6J, S5A, and S5B), indicating that Braf-rs1 3’UTR overexpression elicits a phenotype similar to full-length Braf-rs1. TRE-BPS CDS mice developed lymphomas with a reduced penetrance and aggressiveness compared to mice overexpressing full-length Braf-rs1 or Braf-rs1 3’UTR (Figures 6C and 6D and data not shown). Similarly, infection of TRE-BPS CDS and TRE-BPS 3’UTR MEFs with tTA-pMSCV induced Braf-rs1 CDS and Braf-rs1 3’UTR expression (Figure S5D), but only Braf-rs1 3’UTR elicited a significant effect on B-Raf expression and proliferation, while the Braf-rs1 CDS-induced effects were negligible (Figures S5D–S5G). Braf-rs1 CDS and Braf-rs1 3’UTR may regulate distinct ceRNA networks, but the finding that the severity of the phenotype elicited by the three Braf-rs1 variants correlated with their ability to deregulate B-Raf provides compelling support to the notion that Braf-rs1 operates as a proto-oncogenic ceRNA through B-Raf in B cells.

**BRAFP1 Is an Oncogenic ceRNA in Human Cancer**

Overexpression of human BRAFP1 increased BRAF and pERK levels as well as proliferation of human cells (Figures 1A, 1D, 1G, and 1H), suggesting that BRAFP1 may be an oncogene in human cancer. To explore this possibility further, we first determined whether BRAFP1 is expressed in human DLBCL. Interestingly, BRAFP1 expression was not found in primary human B cells (Figures 7A and S6A) but was detected in 30% of human primary DLBCL and 20% of human DLBCL cell lines (Figures 7A and S6A). Similar observations have been made in the thyroid, where BRAFP1 was expressed in some tumors, but not in normal tissue (Zou et al., 2009). Moreover, BRAFP1 was expressed in melanoma, prostate cancer, and lung cancer cell lines (Figure S6A).

We next interrogated The Cancer Genome Atlas’s (TCGA) cBio Cancer Genomics Portal for genomic abnormalities of the locus containing BRAFP1. As pseudogene data are not yet included in TCGA, we focused our analysis on two protein-coding genes flanking BRAFP1: ZDHHC15 and MAGEE2 (Figure S6B). Notably, concurrent copy-number gains and amplification of ZDHHC15 and MAGEE2 were observed in numerous cancer types (Figure S6B). Importantly, BRAFP1 expression could be detected in such cancer types (Kalyana-Sundaram et al., 2012). Thus, both transcriptional mechanisms and genomic
Figure 7. BRAFP1 in Human Cancer
(A) Percentage of primary human B cells, primary human DLBCL, and human DLBCL cell lines expressing BRAFP1 as determined by qPCR analysis. (B and C) Positive correlation of BRAFP1 and BRAF expression in human DLBCL primary tumors (B) and cell lines (C). (D–G) Western blot for BRAF and pERK in OCI-Ly18 (D), H1299 (E), PC9 (F), and OCI-Ly1 (G) cells in response to BRAFP1 silencing. (H–K) Proliferation of OCI-Ly18 (H), H1299 (I), PC9 (J), and OCI-Ly1 (K) cells in response to BRAFP1 silencing. (L) Western blot for BRAF and pERK in OCI-Ly1 cells overexpressing BRAFP1.

(legend continued on next page)
aberrations may lead to abnormal BRAFP1 expression in human cancer.

Our experiments in human cell lines indicate that BRAFP1 may operate as a ceRNA to regulate BRAF expression. Accordingly, analysis of RNA sequencing data revealed that BRAFP1 and BRAF expression were positively correlated in primary human DLBCL tumors and DLBCL cell lines (Figure 7B and 7C). We also analyzed whether the expression of dual-targeting miRNAs correlates with BRAF and/or BRAFP1 expression. While miR-590 expression negatively correlated with BRAFP1 levels, miR-30a, miR-182, and miR-876 showed no correlation (Figure S6C). Thus, similar to our observations in TRE-BPS MEFs, expression of BRAFP1 and BRAF may not affect miRNA abundance in human DLBCL.

To functionally validate the oncogenic function of BRAFP1 in human cancer, we designed shRNAs to specifically silence expression of endogenous BRAFP1 (Figure S6H). Knockdown of BRAFP1 in OCI-Ly18 DLBCL cells and H1299 and PC9 lung cancer cells reduced the expression of BRAF and pERK (Figures 7D–7F and S6I–S6K). BRAFP1 silencing moderately reduced BRAF mRNA levels in OCI-Ly18 and PC9 cells, but not in H1299 cells, suggesting that the mechanism of miRNA-mediated regulation of BRAF varies between cell lines. Importantly, the BRAFP1 hairpins had no effect on BRAF and pERK expression in OCI-Ly1 DLBCL cells that do not express endogenous BRAFP1 (Figure 7G). Moreover, BRAFP1 silencing reduced proliferation of OCI-Ly18, H1299, and PC9 cells, but not of OCI-Ly1 cells (Figures 7H–7K). Remarkably, silencing of endogenous BRAFP1 elicited a significant effect on BRAF expression in OCI-Ly18, H1299, and PC9 cells even though it is ~15- to ~30-fold less abundant than BRAF (Figures S6D and S6E). Intriguingly, BRAFp1 was turned over significantly faster than BRAF (Figure S6F), suggesting that the relatively low expression levels of BRAFP1 may be due to its short half-life. We also determined the abundance of miR-30a, miR-182, and miR-876 in OCI-Ly18, H1299, and PC9 cells and found that their expression levels were in the same range as those of BRAFP1 and BRAF (Figures S6G).

Overexpression of BRAFP1 in three human DLBCL cell lines lacking endogenous BRAFP1 expression, SU-DHL-4, Karpas422, and OCI-Ly1 (Figures S6A and S6L), resulted in elevated BRAF and pERK levels (Figures 7L and S6M). Moreover, BRAFP1 overexpression increased proliferation of all three DLBCL cell lines (Figures 7M, S6N, and S6O) and resulted in increased growth of xenotransplanted OCI-Ly1 cells in the bone marrow of NSG recipients (Figure 7N). These data suggest that BRAFP1 has oncogenic properties in human cancer.

**DISCUSSION**

We investigated whether pseudogenes exert critical functions in the context of a whole organism and whether their perturbation contributes to the development of disease. We focused on the BRAF pseudogene, as it exists in humans and mice and is deregulated in cancer (Kalyana-Sundaram et al., 2012; Zou et al., 2009). Our study establishes the BRAF pseudogene as a potent proto-oncogene that can elicit a phenotype resembling human diffuse large B cell lymphoma. Remarkably, no additional engineered mutations were required to drive this phenotype, and lymphomas completely regressed upon Dox withdrawal, emphasizing the oncogenic potential of the BRAF pseudogene. While it is possible that the BRAF pseudogene elicits its effects through more than one mechanism or pathway, the fact that both the CDS and the 3’ UTR of Braf-rs1 displayed a similar phenotype to full-length Braf-rs1, albeit with different severity, supports the notion that Braf-rs1 functions as a ceRNA to regulate B-Raf in vivo (Figure 7O). Whether the oncogenic activity of Braf-rs1 also requires additional ceRNA targets or non-ceRNA-related mechanisms will be the focus of future studies.

Several groups, including ours, have generated mathematical models to quantitatively assess the response of a ceRNA network to perturbations (Ala et al., 2013; Bosia et al., 2013; Figliuzzi et al., 2013). More recently, such models were used in conjunction with miRNA predictions, RNA sequencing, and target site occupancy analyses to more accurately characterize miRNA competition (Boisson et al., 2014; Denzler et al., 2014; Jens and Rajewsky, 2014). Intriguingly, these studies yielded disparate conclusions. It was proposed that ceRNA crosstalk is unlikely to occur upon physiological changes of ceRNA expression based on these models’ estimates of the number of additional target sites required to achieve significant expression changes of other targets (Denzler et al., 2014; Jens and Rajewsky, 2014). By contrast, using Argonaute iCLIP and RNA-seq, Sharp and colleagues determined that a relatively low number of additional target sites could elicit ceRNA crosstalk when the number of miRNA molecules and high-affinity target sites approaches equimolarity (Boisson et al., 2014). Interestingly, BRAFP1 is several-fold less abundant than BRAF, yet its silencing significantly diminished BRAF expression levels, MAPK signaling, and proliferation. BRAF and its pseudogene harbor high-affinity sites for the murine and human miRNAs that we validated as potential mediators of the ceRNA crosstalk (miR s-134, -543, and -653 and miRs-30a, -182, -876, respectively). Notably, the levels of these miRNAs in mouse spleens and lymphomas as well as human cancer cell lines are amenable to miRNA competition in accordance with the model proposed by Boisson et al. Thus, a ceRNA effect of BRAFP1 that is solely based on miRNA competition may be compatible with this model.

Importantly, the studies by the groups of Sharp, Stoffel, and Rajewsky focused on ceRNA regulation that is mediated by a single miRNA. However, ceRNA pairs in general, and gene/pseudogene pairs in particular, share numerous miRNAs. This increases the likelihood of shared miRNAs being present at cross-talk-favoring levels, and we have shown that ceRNA crosstalk is enhanced when it is mediated by more miRNAs (Ala et al., 2013).
As discussed by Jens and Rajewsky, several factors that may influence ceRNA crosstalk are neglected in current mathematical models. For instance, subcellular co-localization of miRNAs and competing targets may result in local concentrations that favor ceRNA crosstalk. In addition, target degradation may trap miRNAs in P bodies or other sites of RNA decay, thus amplifying the ceRNA regulation by removing miRNAs from the available pool. Intriguingly, BRAFP1 is degraded significantly faster than BRAF (Figure S6F); however, whether this influences the ceRNA activity of BRAFP1 remains to be determined. Future improvements to both quantitative measurements and mathematical models will undoubtedly provide a better understanding of the molecular conditions required for ceRNA crosstalk. However, it should be noted that ceRNA crosstalk can be predicted solely based on the MRE overlap of transcripts (Chiu et al., 2014; Karreth et al., 2011; Sumazin et al., 2011; Tay et al., 2011), suggesting that miRNA competition is indeed the central component of ceRNA crosstalk.

Human hematopoietic malignancies are associated with “overdosage” of the X chromosome, which harbors the BRAF pseudogene locus. This can occur through XIST deletion and X chromosome duplication in women with myeloid cancers, and extra X chromosomes have been noted in a variety of hematopoietic cancers of both sexes (Dewald et al., 1989; Dierlamm et al., 1995; Heinonen et al., 1999; Paulsson et al., 2010; Rack et al., 1994; Yamamoto et al., 2002), including DLBCL (Bea et al., 2005; Monni et al., 1996; Morin et al., 2013). Our analysis revealed that a variety of human cancers harbor copy-number gains and amplifications of the locus containing BRAFP1. It is therefore tempting to speculate that increased X dosage and the potentially associated overexpression of BRAFP1 contribute to the development and/or progression of cancer cases harboring more than one active copy of the X chromosome. Moreover, elevated expression of BRAFP1 has been observed in cancers other than DLBCL (Kalyana-Sundaram et al., 2012; Zou et al., 2009), and transcriptional deregulation may thus be another means to deregulate BRAF expression. Whether BRAFP1 has oncogenic potential in other organs such as the thyroid remains to be determined through the use of tissue-specific overexpression of the BRAF pseudogene.

Interestingly, several observations suggest that the BRAF pseudogenes evolved independently in mice and humans. First, they reside in non-syngeneic locations—on chromosome 10 in mice and on the X chromosome in humans. Second, the 3′ UTR of the BRAF gene is not conserved between mice and humans; importantly, however, the BRAF pseudogene 3′ UTRs display high sequence homology to their parental pseudogene. The likely parallel yet converging dimension of the transcriptome and should stimulate further studies of the role of pseudogenes in the development of disease.

**Experimental Procedures**

**Flow Cytometry**

Mice were euthanized and single-cell suspensions from spleens and lymph nodes were prepared by passing organs through 100 μm cell striainers in 2% FBS/PBS, centrifuged and re-suspended in 1–2 ml ACK red cell lysis buffer (GIBCO). Red blood cells were lysed on ice for 1 min. Cell suspensions were then washed in 2% FBS/PBS, centrifuged and re-suspended in 1 ml 2% FBS/PBS. For hematopoietic lineage analysis, we used monoclonal antibodies specific for the following: CD3e-PE (145-2C11), B220-FITC (RA3-6B2), Gr-1-APC (RB6-8C5), and CD11b-PE/Cy7 (M1/70). All antibodies were from eBioscience. To assess cell viability, cells were incubated with DAPI prior to FACS analysis. All staining mixtures were analyzed on a BD LSR II flow cytometer (Becton Dickinson). Resulting profiles were further processed and analyzed using the FlowJo 8.7 software. For fold change quantifications, both mutant and control cell populations were normalized to the average of the controls. At least five mice from different litters were used for all flow cytometry experiments.

**Tissue Fixation, H&E, and IHC**

Tissues were fixed in 4% paraformaldehyde overnight and embedded in paraffin according to standard procedures. 5 μm sections were either stained with hematoxylin & eosin or with the following antibodies: CD45R/B220 (ab64100, Abcam), CD3 (ab5690, Abcam), Ki-67 (RM-9106-S1, Thermo Scientific), IgG (BA2000, Vector), BRAF (sc-9002, Santa Cruz), pERK (4373, Cell Signaling), Bcl-6 (6560, Cell Signaling), and Mum1 (sc-6059, Santa Cruz). Organs from at least five mice from different litters were used for all stainings.

**Cell Culture**

HCT116 and HeLa were from ATCC, Dicer mutant HCT116 cells were provided by B. Vogelstein, and Dicer+/− and Dicer+/+ mouse sarcoma cells were provided by P. Sharp and were cultured in DMEM containing 10% FCS and 2 mM L-glutamine. PC9, H1299, H441, and H2009 (all provided by L. Cantley), OCI-Ly6, OCI-Ly3, RCK8, and Val were grown in RPMI-1640 containing 10% FCS and 2 mM L-glutamine. SU-DHL-4, SU-DHL-8, Karpos422, OCI-Ly7, Toledo, OCI-Ly1, and OCI-Ly18 cells were grown as previously described.
Plasmids, Transfection, and Virus Infection
Human BRFAP1 was cloned into pLenti-CMV-GFP-Puro (Addgene 25873) and pCDNA3, and mouse Braf-rs1 was cloned into pCCL.sin.PPT.hPKG
GFp.Wpre (L277, L. Naldini) or pCDNA3-neo. pMSCV-ITA (Addgene #18783) was used to induce Braf-rs1 expression in TRE-BPS MEFs. Lipofectamine 2000 was used for plasmid transfection. Lentivirus or retrovirus was produced in HEK293T Lentiv X cells (Clontech) co-transfected with VSVG, PMDL, and Rev or Eco helper plasmids, respectively. Viral supernatants were filtered and cells infected in the presence of 5 μg/ml polybrene.

Proliferation Assays
For proliferation assays, 2 × 10^5 cells were plated in four 12-well plates in triplicates. Every day, one plate was fixed with 4% paraformaldehyde and stained with Crystal Violet. The dye was extracted with 10% acetic acid and its absorbance determined at OD595. For suspension cells, 1 × 10^6 cells were plated in triplicates in round-bottom 96-well plates and counted every day for 5 days.

Luciferase Assays
HCT116 cells were transfected with 150 ng of psiCHECK2 vector or psiCHECK2-humanBRAF 3' UTR and 1 ng human BRFAP1 constructs using Lipofectamine 2000. To validate miRNA targeting, 3' UTRs of murine and human gene and pseudogene were cloned into psiCHECK2. 5 × 10^4 HEK293T cells were transfected in 48-well plates with 20 ng of psiCHECK2 reporter and 100 nM miRNA mimics (QIAGEN). To test the ceRNA activity of the BRAF pseudogenes, 5 × 10^4 HEK293T cells were transfected in 48-well plates with 20 ng of psiCHECK2 reporter and 250 ng of murine Braf-rs1-L277 vector or human BRFAP1-pCDNA3-1–2 nM miRNA mimics. In all transfections, firefly luciferase activity was used as a normalization control for transfection efficiency. 48 hr after transfection, luciferase activities were measured consecutively with the dual luciferase reporter system (Promega).

Western Blot
Cells were lysed in RIPA buffer containing HALT protease and phosphatase inhibitors (Sigma). 20 μg total protein were separated on 4%–12% Bis-Tris acrylamide NuPAGE gradient gels in MOPS SDS buffer (Invitrogen). The following antibodies were used: HSP90 (610419, BD), BAF (sc5284, Santa Cruz), pERK (9101, Cell Signaling), and tERK (9102, Cell Signaling). Secondary HRP-tagged antibodies and ECL detection reagent were from Amersham. Image J software was used for quantification.

SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, six figures, and two tables and can be found with this article online at http://dx.doi.org/10.1016/j.cell.2015.02.043.

REFERENCES


